Immune Checkpoints as Therapeutic Targets in Autoimmunity

Area of Science:

• Immunology
• Oncoimmunology
• Autoimmunity

Background:

• Immune checkpoint inhibitors targeting PD1 and CTLA4 are effective cancer therapies.
• These therapies can lead to immune-related adverse events due to loss of self-tolerance.
• Immune checkpoint receptors play a critical role in modulating physiological immune responses.

Purpose of the Study:

• To discuss the rationale for using agonistic agents to target immune checkpoint receptors in autoimmunity.
• To review current progress in developing therapies to restore immune tolerance.
• To explore mechanisms of immune cell modulation by these receptors for future therapeutic design.

Main Methods:

• Review of existing literature on immune checkpoint modulation.
• Analysis of therapeutic strategies using Fc-fusion proteins and monoclonal antibodies.
• Exploration of potential mechanisms of immune cell signaling.

Main Results:

• Therapeutic blockade of PD1 and CTLA4 demonstrates their role in maintaining self-tolerance.
• Agonistic agents are being developed to induce immunosuppressive signaling.
• Progress has been made in utilizing various constructs for tolerance induction.

Conclusions:

• Targeting immune checkpoint receptors with agonists offers a potential strategy for treating autoimmune diseases.
• Understanding receptor-mediated immune cell modulation is key to designing effective tolerance-inducing therapies.
• Further research into these mechanisms may lead to improved treatments for autoimmunity.